Izumiyama K, Inao T, Goto H, Harada S, et al. Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group. Haematologica 2024 Jun 13. doi: 10.3324/haematol.2023.284841.
PMID: 38867578